Pfizer launched the study in November 2022, but has not publicly released interim data and now says the study won’t be complete until November 2030. Some experts said the vaccine maker may be attempting to delay disclosure of data that could raise questions about the vaccine’s safety.Pfizer is drawing criticism for delaying — until November 2030 — completion of its myocarditis safety study in children and young adults under 21.SNIPLast month, the U.S. Food and Drug Administration (FDA) approved updated versions of package inserts for the Pfizer and Moderna COVID-19 vaccines to include stronger warnings about the risks of myocarditis...